制药公司 长风药业 (02652)发布公告，公司全球发售约4119.8万股股份，香港公开发售占10%，国际发售占90%。最终发售价为每股14.75港元，全球发售净筹约5.25亿港元。每手500股，预期将于2025年10月8日(星期三)上午九时正(香港时间)开始在联交所买卖。
长风药业于香港公开发售获26.4万份认购，超购6696.8倍，一手中签率为1%，甲、乙组都未能稳中一手。而上限认购206万股的「顶头槌飞」有3514名，当中有1501名获发一手。长风药业国际发售获12.74倍认购。
制药公司 长风药业 (02652)发布公告，公司全球发售约4119.8万股股份，香港公开发售占10%，国际发售占90%。最终发售价为每股14.75港元，全球发售净筹约5.25亿港元。每手500股，预期将于2025年10月8日(星期三)上午九时正(香港时间)开始在联交所买卖。
长风药业于香港公开发售获26.4万份认购，超购6696.8倍，一手中签率为1%，甲、乙组都未能稳中一手。而上限认购206万股的「顶头槌飞」有3514名，当中有1501名获发一手。长风药业国际发售获12.74倍认购。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.